Pregled bibliografske jedinice broj: 75693
Sertraline-mediated endocrine effects in depressed patients
Sertraline-mediated endocrine effects in depressed patients // Abstracts of the Third meeting of the Federation of European Pharmacological Societies (EPHAR) ; u: Fundamental and Clinical Pharmacology 15 (2001) (S1) ; Posters 64-106 ; 8P113 / Bousquet, Pascal (ur.).
Strasbourg: Wiley-Blackwell, 2001. str. 82-82 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 75693 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Sertraline-mediated endocrine effects in depressed patients
Autori
Pivac, Nela ; Muck-Šeler, Dorotea ; Šagud, Marina ; Jakovljević, Miro
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the Third meeting of the Federation of European Pharmacological Societies (EPHAR) ; u: Fundamental and Clinical Pharmacology 15 (2001) (S1) ; Posters 64-106 ; 8P113
/ Bousquet, Pascal - Strasbourg : Wiley-Blackwell, 2001, 82-82
Skup
Meeting of the Federation of European Pharmacological Societies (()3 ; 2001)
Mjesto i datum
Lyon, Francuska, 06.07.2001. - 09.07.2001
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
sertraline; plasma cortisol; prolactin and thyroid hormones
Sažetak
Depression is related to the changes in various neurotransmitter systems and in the altered activity of the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-thyroid (HPT) axis. The aim of the present study was to evaluate the effects of short-term (4 weeks) and long-term (24 weeks) sertraline (average dose 42.5 mg/day, PO) treatment, a potent selective serotonin reuptake inhibitor, on HPA and HPT activity in 15 female nonpsychotic, depressed patients. The effects of sertraline were evaluated at the beginning of the treatment (baseline), and after 4 and 24 weeks of sertraline treatment, using Montgomery-Asperg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating Scale (HAMD), and Clinical Global Impression Scale (CGI), on plasma concentrations of cortisol, prolactin, thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxin (T4). Significant clinical improvement in symptoms of depression was observed after long-term sertraline treatment, as indicated in the reduction in MADRS, HAMD and CGI scores. The results of the study show 47% responders after 4 and 87% responders after 24 weeks of sertraline treatment, a short-term sertraline treatment-induced increase of plasma cortisol, and a long-term treatment-induced rise of plasma T3 concentration, with no correlation between MADRS scores and particular hormons. Neither short-, nor long-term sertraline treatment affected plasma levels of PRL, T4 and TSH. Our data show antidepressant effects of sertraline in the treatment of major depression and suggest different and time dependent effect of sertraline on the activity of the HPA and HPT axis in female depressed patients.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
Napomena
DOI: 10.1046/j.1472-8206.2001.00064.x
POVEZANOST RADA
Projekti:
00980001
Ustanove:
Institut "Ruđer Bošković", Zagreb
Profili:
Marina Šagud
(autor)
Dorotea Muck-Šeler
(autor)
Miro Jakovljević
(autor)
Nela Pivac
(autor)